1Salomon D S, Brandt R, Ciardiello F.et al. Epidermal growth factor-related pcptide and receptors in human malignancies[J].Crit Rev Oncol Hematol, 1995,19(3) :183
2Harai P M, Huang S M. Modulation of molecular targets to enhance radiation[J]. Clin Cancer Rcs, 2000,6(2) :323
3Baselga J, Herbst R, Lorusso P, et al. Constinuous administration of ZD1839, a novel oral epidermal growth factor receptor tyrosinc kinase inhibitir , in patients with five selected tumor types: evidence of activity and good tolerability [A].Proc Am Soc Clin Oncol, 2000,19:177a
4Ferry D, Hammond L, Ranson M, et al. Intermittcnt oral ZD1839, a novel epidermal growth factor receptor tyrosine kinase inhibitor shows early evidence of good tolerability and activity: Final results from a phase I study [J]. Proc Am Soc Clin Oncol, 2000,19: 3a.
5Goldstein N S, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage Ⅳ colon adcnocarcinoma:implications for a standardized scoring system [J]. Cancer,2001, 92(5) :1331
6De Luca A, Pignata S, Casamassini A, et al. Detection of circulating tumor cells in carcinoma patients by a novel epidermal growth factor receptor reverse transcription-PCR assay [J].Clin Cancer Res, 2000,6(4): 1439
7Herbst R S, Shin D M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumours: a new paradigm for cancer therapy[J ]. Cancer, 2002,94 (5): 1593
8Liu B, Fang M, Schmidt M, et al. Induction of apoptosis and activition of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the Cjun N-terminal kinase activity [J]. Br J Cancer, 2000,82(12):1991
9Kannan S, De Santis M, Lohmeyer M, et al. Cripto enhances the tyrosine phosphorylation of She and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells [J]. J Biol Chem, 1997, 272(6):3330
10Massague J. Transforming growth factor-alpha, A model for membrane-anchored growth factors [J]. J Biol Chem, 1990,265(35):21393
9Lockhart C, Berlin J D. The epidermal growth factor receptor as a target for colorectal cancer therapy[J]. Semin Oncol,2005,32 (1) :52-60.
10Suzuki A, Hayashida M, Ito T, et al. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16 (INK4a) and Cdk2/eyelin E complex activation[J]. Oncogene,2000,19(29):3225-3234.
